Search results
Results from the WOW.Com Content Network
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. [35] [36] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster. [37]
In September 2023, the FDA approved an updated a monovalent (single) component Omicron variant XBB.1.5 version of the vaccine (Spikevax 2023-2024 formula) as a single dose for individuals aged twelve years of age and older; [203] and authorized the Moderna COVID-19 Vaccine 2023-2024 formula under emergency use for individuals aged 6 months ...
The U.S. Food and Drug Administration has approved updated COVID-19 vaccines from Moderna and Pfizer/BioNTech as case counts continue to rise.. The new vaccine, which is approved for anyone over ...
The U.S. Food and Drug Administration approved and granted emergency use authorization Thursday for updated COVID-19 vaccines for the upcoming fall and winter season. The FDA said the vaccines ...
Millions of updated COVID-19 vaccines will soon be ready for patients following Food and Drug Administration approval announced on Thursday. The updated vaccines from Pfizer and Moderna for people ...
In August 2024, the FDA approved and granted emergency authorization for a monovalent Omicron KP.2 version of the Pfizer–BioNTech COVID-19 vaccine. [78] In June 2024, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines. [78]
This photo provided by Pfizer in August 2024 shows a packaging for the company's updated COVID vaccine for ages 12 and up, approved by the U.S. Food and Drug Administration on Thursday, Aug. 22, 2024.